Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib

Pediatr Blood Cancer. 2021 Jun;68(6):e28954. doi: 10.1002/pbc.28954. Epub 2021 Mar 10.

Affiliations

¹ Immunology and Rheumatology Division, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada.
² Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, Québec, Canada.
³ Hematology-Oncology Division, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada.

PMID: 33694335
DOI: 10.1002/pbc.28954

No abstract available

Publication types

Letter

MeSH terms

Humans
Lymphohistiocytosis, Hemophagocytic* / drug therapy
Nitriles
Pyrazoles
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib